Cancer Unfiltered

Can a simple blood test tell us when to switch, stop, or add breast cancer treatment?

In Episode 5 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar are joined by Dr. Heather Parsons and patient advocate Julia Maués to explore the evolving role of circulating tumor DNA (ctDNA) in breast cancer treatment decisions.

From SERENA-6 and switching therapy before radiographic progression to HER2CLIMB-05, the STOP-HER2 trial, and AFT-70 NAVIGATE, the conversation examines how ctDNA could help guide treatment escalation, de-escalation, and personalized care.

Beyond the data, they tackle the unanswered questions: When should clinicians act on molecular findings? Can some patients safely stop treatment? And how do we balance promising innovations with treatment burden, toxicity, and patient preferences?

▶️ Watch on YouTube - https://youtu.be/Mh2uNBGrRLI

🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio: https://linkin.bio/cancerunfiltered

Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#CancerUnfiltered #ctDNA #BreastCancer #SERENA6 #STOPHER2 #NAVIGATETrial #MetastaticBreastCancer #PrecisionOncology #MedicalOncology #CommunityHealthMedia

One trial. One therapy. Countless clinical questions.

In Episode 4 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar take a deep dive into the VIKTORIA-1 trial and discuss how gedatolisib may reshape treatment for patients with HR-positive, HER2-negative metastatic breast cancer.

Beyond reviewing the data, they explore where this regimen fits in clinical practice, who may benefit most, concerns surrounding toxicity and treatment burden, and how VIKTORIA-1 compares with other rapidly emerging therapies in this evolving treatment landscape.

Topics discussed:

VIKTORIA-1 trial design and key efficacy results

Gedatolisib triplet vs. doublet therapy

Managing HR-positive, HER2-negative metastatic breast cancer

Intravenous therapy vs. oral treatment options

Stomatitis and other treatment-related toxicities

Patient selection and co-mutations

How PAM pathway inhibition may overcome resistance

Sequencing endocrine therapies after progression

Emerging trials including FOURLIGHT-1 and selective CDK4 inhibitors

The future of targeted therapy in metastatic breast cancer

Recorded prior to the July 2026 FDA approval of gedatolisib (Revtorpyk) with fulvestrant, ± palbociclib, for HR-positive, HER2-negative advanced breast cancer without a detectable PIK3CA mutation after progression on prior endocrine therapy.

▶️ Watch on YouTube - https://youtu.be/43BVZ9nL424

🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - https://linkin.bio/cancerunfilteredpodcast/

#CancerUnfiltered #VIKTORIA1 #Gedatolisib #HRPositive #MetastaticBreastCancer #MedicalOncology #BreastCancer #PI3K #PIK3CA #TargetedTherapy #CommunityHealthMedia

Breast cancer treatment is changing at an unprecedented pace.

In Episode 3 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar discuss the latest FDA approvals, landmark clinical trials, and emerging treatment strategies that are reshaping care across HR-positive, HER2-positive, and triple-negative breast cancer. From practice-changing DESTINY data to the expanding role of antibody-drug conjugates, this episode breaks down what the latest evidence means for treatment decisions today.

Topics discussed:

• Six new FDA approvals across all major breast cancer subtypes

• Vepdegestrant and the VERITAC-2 trial for ESR1-mutant HR-positive breast cancer

• DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09: key findings and clinical impact

• The growing role of antibody-drug conjugates (ADCs) in first-line metastatic triple-negative breast cancer

• Treatment sequencing and how new approvals are changing clinical decision-making

• Which HER2-positive patients may benefit most from the DESTINY-Breast09 approach

• Brain metastases, PIK3CA mutations, and selecting therapy for high-risk patients

• Giredestrant and the lidERA trial: improving endocrine therapy options

• VIKTORIA-1 and emerging therapies targeting the PI3K/AKT/mTOR (PAM) pathway

• The future of breast cancer treatment and practice-changing data to watch

Whether you're an oncologist, advanced practice provider, researcher, or healthcare professional, this episode offers practical insights into the rapidly evolving breast cancer treatment landscape and what these developments mean for patient care.

▶️ Watch on YouTube - https://youtu.be/m0l8feuG6Y8

🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered

Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #FDAApprovals #DESTINYBreast11 #DESTINYBreast05 #Vepdegestrant #TripleNegativeBreastCancer #HER2Positive #CancerPodcast #CommunityHealthMedia

The conversation continues.

In Episode 2 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar break down the biggest updates from ESMO Breast 2026, including DESTINY-Breast11, SERENA-6, ctDNA monitoring, exercise and metabolic health, emerging novel therapies, and the future of ER-positive breast cancer treatment.

From controversial questions surrounding molecular progression to exciting new therapies in development, this episode explores where breast cancer care is heading next.

If Episode 1 introduced the conversation, Episode 2 takes it even further.

▶️ Watch on YouTube - https://youtu.be/Bq6HCsyn7b4

🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered

Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#CancerUnfiltered #ESMOBreast2026 #BreastCancer #Oncology #MedicalOncology #ERPositive #HER2Positive #ctDNA #SERENA6 #CancerPodcast #HealthcareEducation #CommunityHealthMedia

Before the data drops, the hot takes, and the controversies, there was Miami.

In this special bonus episode, Dr. Komal Jhaveri and Dr. Neil Iyengar introduce Cancer Unfiltered and discuss the biggest questions shaping breast oncology today.

From oral SERDs and overcoming ESR1 mutations to the monotherapy vs. combination debate, ADC sequencing, first-line triple-negative breast cancer strategies, and the real-world application of precision medicine, this conversation lays the foundation for everything that follows.

This is where Cancer Unfiltered began.

▶️ Watch on YouTube - https://youtu.be/sMbRsnGNamQ

🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered

Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #ESR1 #OralSERD #ADC #TripleNegativeBreastCancer #MetastaticBreastCancer #CancerPodcast #CommunityHealthMedia

The conversations oncology has been waiting for are finally here.

Welcome to the very first episode of Cancer Unfiltered with Dr. Komal Jhaveri & Dr. Neil Iyengar.

From SERDs and ctDNA to resistance mechanisms, NGS profiling, T-DXd, and the future of metastatic breast cancer treatment, nothing is off limits. Real conversations. Real controversies. Real clinical insight.

This is oncology without the filters.

FULL EPISODE OUT NOW!

▶️ Watch on YouTube - https://youtu.be/7cIohpPZoIo

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music - https://linkin.bio/cancerunfiltered

Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #MetastaticBreastCancer #HER2Positive #ERPositive #TDXd #NGS #ctDNA #SERD #CancerPodcast #HealthcareEducation #CommunityHealthMedia

What happens when two leading breast oncologists sit down for an unfiltered conversation on the biggest breakthroughs, controversies, and real-world challenges in breast cancer today?

In Episode 1 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar break down the latest data in metastatic breast cancer, including SERENA-6, PATINA, HER2CLIMB-05, DB-09, oral SERDs, ctDNA monitoring, and the evolving future of personalized treatment strategies.

From hot takes on HER2-positive disease to real patient cases that highlight the complexity of ER-positive metastatic breast cancer, this episode dives into the clinical decisions shaping breast oncology today.

▶️ Watch on YouTube - https://youtu.be/7cIohpPZoIo

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music - https://linkin.bio/cancerunfiltered

Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.

#CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #HER2Positive #ERPositive #MetastaticBreastCancer #ESR1 #ctDNA #OralSERD #BreastCancerResearch #ASCO #CancerPodcast #HealthcareEducation #CommunityHealthMedia